Embryonic stem cell in the context of Immunosurgery


Embryonic stem cell in the context of Immunosurgery

Embryonic stem cell Study page number 1 of 1

Play TriviaQuestions Online!

or

Skip to study material about Embryonic stem cell in the context of "Immunosurgery"


⭐ Core Definition: Embryonic stem cell

Embryonic stem cells (ESCs) are pluripotent stem cells derived from the inner cell mass of a blastocyst, an early-stage pre-implantation embryo. Human embryos reach the blastocyst stage 4–5 days post fertilization, at which time they consist of 50–150 cells. Isolating the inner cell mass (embryoblast) using immunosurgery results in destruction of the blastocyst, a process which raises ethical issues, including whether or not embryos at the pre-implantation stage have the same moral considerations as embryos in the post-implantation stage of development.

Researchers focus heavily on the therapeutic potential of embryonic stem cells, with clinical use being the goal for many laboratories. Potential uses include the treatment of diabetes and heart disease. The cells are studied to be used as clinical therapies, models of genetic disorders, and cellular/DNA repair. However, adverse effects in the research and clinical processes such as tumors and unwanted immune responses have also been reported.

↓ Menu
HINT:

👉 Embryonic stem cell in the context of Immunosurgery

Immunosurgery is a method of selectively removing the external cell layer (trophoblast) of a blastocyst through a cytotoxicity procedure. The protocol for immunosurgery includes preincubation with an antiserum, rinsing it with embryonic stem cell derivation media to remove the antibodies, exposing it to complement, and then removing the lysed trophoectoderm through a pipette. This technique is used to isolate the inner cell mass of the blastocyst. The trophoectoderm's cell junctions and tight epithelium "shield" the ICM from antibody binding by effectively making the cell impermeable to macromolecules.

Immunosurgery can be used to obtain large quantities of pure inner cell masses in a relatively short period of time. The ICM obtained can then be used for stem cell research and is better to use than adult or fetal stem cells because the ICM has not been affected by external factors, such as manually bisecting the cell. However, if the structural integrity of the blastocyst is compromised prior to the experiment, the ICM is susceptible to the immunological reaction. Thus, the quality of the embryo used is imperative to the experiment's success. In addition, when using complement derived from animals, the source of the animals matters. They should be kept in a specific-pathogen-free environment to increase the likelihood that the animal has not developed natural antibodies against the bacterial carbohydrates present in the serum (which can be obtained from a different animal).

↓ Explore More Topics
In this Dossier

Embryonic stem cell in the context of Martin Evans

Sir Martin John Evans FRS FMedSci FLSW (born 1 January 1941) is an English biologist who, with Matthew Kaufman, was the first to culture mice embryonic stem cells and cultivate them in a laboratory in 1981. He is also known, along with Mario Capecchi and Oliver Smithies, for his work in the development of the knockout mouse and the related technology of gene targeting, a method of using embryonic stem cells to create specific gene modifications in mice. In 2007, the three shared the Nobel Prize in Physiology or Medicine in recognition of their discovery and contribution to the efforts to develop new treatments for illnesses in humans.

He won a major scholarship to Christ's College, Cambridge at a time when advances in genetics were occurring there and became interested in biology and biochemistry. He then went to University College London where he learned laboratory skills supervised by Elizabeth Deuchar. In 1978, he moved to the Department of Genetics, at the University of Cambridge, and in 1980 began his collaboration with Matthew Kaufman. They explored the method of using blastocysts for the isolation of embryonic stem cells. After Kaufman left, Evans continued his work, upgrading his laboratory skills to the newest technologies, isolated the embryonic stem cell of the early mouse embryo and established it in a cell culture. He genetically modified and implanted it into adult female mice with the intent of creating genetically modified offspring, work for which he was awarded the Nobel Prize in 2007. In 2015, he was elected a Fellow of the Learned Society of Wales. Today, genetically modified mice are considered vital for medical research.

View the full Wikipedia page for Martin Evans
↑ Return to Menu

Embryonic stem cell in the context of Dolly (sheep)

Dolly (5 July 1996 – 14 February 2003) was a female Finn-Dorset sheep and the first mammal that was cloned from an adult somatic cell. She was cloned by associates of the Roslin Institute in Scotland, using the process of nuclear transfer from a cell taken from a mammary gland. Her cloning proved that a cloned organism could be produced from a mature cell from a specific body part. Contrary to popular belief, she was not the first animal to be cloned.

The employment of adult somatic cells in lieu of embryonic stem cells for cloning emerged from the foundational work of John Gurdon, who cloned African clawed frogs in 1958 with this approach. The successful cloning of Dolly led to widespread advancements within stem cell research, including the discovery of induced pluripotent stem cells.

View the full Wikipedia page for Dolly (sheep)
↑ Return to Menu

Embryonic stem cell in the context of Project 2025

Project 2025 (also known as the 2025 Presidential Transition Project) is a political initiative published in April 2023 by the Heritage Foundation think tank to reshape the federal government of the United States and consolidate executive power in favor of right-wing policies. It constitutes a policy document that suggests specific changes to the federal government, a personnel database for recommending vetting loyal staff in the federal government, and a set of proposed executive orders for the U.S. president to implement those policies.

The project's policy document Mandate for Leadership calls for the replacement of federal civil service workers by people loyal to "the next conservative president" and for taking partisan control of key government agencies, including the Department of Justice (DOJ), the Federal Bureau of Investigation (FBI), the Department of Commerce (DOC), and the Federal Trade Commission (FTC). Other agencies, including the Department of Homeland Security (DHS) and the Department of Education (ED), would be dismantled. It calls for reducing environmental regulations to favor fossil fuels and proposes making the National Institutes of Health (NIH) less independent while defunding its stem cell research. The blueprint seeks to reduce taxes on corporations, institute a flat income tax on individuals, cut Medicare and Medicaid, and reverse as many of President Joe Biden's policies as possible. It proposes banning pornography, removing legal protections against anti-LGBT discrimination, and ending diversity, equity, and inclusion (DEI) programs while having the DOJ prosecute anti-white racism. The project recommends the arrest, detention, and mass deportation of illegal immigrants, and deploying the U.S. Armed Forces for domestic law enforcement. The plan also proposes enacting laws supported by the Christian right, such as criminalizing the sending and receiving of abortion and birth control medications and eliminating coverage of emergency contraception.

View the full Wikipedia page for Project 2025
↑ Return to Menu

Embryonic stem cell in the context of Oct-4

Oct-4 (octamer-binding transcription factor 4), also known as POU5F1 (POU domain, class 5, transcription factor 1), is a protein that in humans is encoded by the POU5F1 gene. Oct-4 is a homeodomain transcription factor of the POU family. It is critically involved in the self-renewal of undifferentiated embryonic stem cells. As such, it is frequently used as a marker for undifferentiated cells. Oct-4 expression must be closely regulated; too much or too little will cause differentiation of the cells.

Octamer-binding transcription factor 4, OCT-4, is a transcription factor protein that is encoded by the POU5F1 gene and is part of the POU (Pit-Oct-Unc) family. OCT-4 consists of an octamer motif, a particular DNA sequence of AGTCAAAT that binds to their target genes and activates or deactivates certain expressions. These gene expressions then lead to phenotypic changes in stem cell differentiation during the development of a mammalian embryo. It plays a vital role in determining the fates of both inner mass cells and embryonic stem cells and has the ability to maintain pluripotency throughout embryonic development. Recently, it has been noted that OCT-4 not only maintains pluripotency in embryonic cells but also has the ability to regulate cancer cell proliferation and can be found in various cancers such as pancreatic, lung, liver and testicular germ cell tumors in adult germ cells. Another defect this gene can have is dysplastic growth in epithelial tissues which are caused by a lack of OCT-4 within the epithelial cells.

View the full Wikipedia page for Oct-4
↑ Return to Menu

Embryonic stem cell in the context of Homeobox protein NANOG

Homeobox protein NANOG (hNanog) is a transcriptional factor that helps embryonic stem cells (ESCs) maintain pluripotency by suppressing cell determination factors. hNanog is encoded in humans by the NANOG gene. Several types of cancer are associated with NANOG.

View the full Wikipedia page for Homeobox protein NANOG
↑ Return to Menu

Embryonic stem cell in the context of Stem cell controversy

The stem cell controversy concerns the ethics of research involving the development and use of human embryos. Most commonly, this controversy focuses on embryonic stem cells. Not all stem cell research involves human embryos. For example, adult stem cells, amniotic stem cells, and induced pluripotent stem cells do not involve creating, using, or destroying human embryos, and thus are minimally, if at all, controversial. Many less controversial sources of acquiring stem cells include using cells from the umbilical cord, breast milk, and bone marrow, which are not pluripotent.

View the full Wikipedia page for Stem cell controversy
↑ Return to Menu